Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA7 | P43166 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9683256 | 0.82 | CYP1A2 (0.39) | CA1CA2CA7CA9CA12 | |
| SCHEMBL17593380 | 0.81 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2AKDM4EHSD17B10 | |
| SCHEMBL1067511 | 0.80 | ALOX15 (0.34) | ALDH1A1MEN1MAPTKMT2ATSHR | |
| SCHEMBL7234655 | 0.78 | TAAR1 (0.41) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL1067461 | 0.77 | GPR3 (0.38) | CYP1A2CYP3A4KDM4EHSD17B10RAB9A | |
| SCHEMBL7482706 | 0.76 | ABCB11 (0.37) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL11567095 | 0.74 | CA4 (0.39) | ALDH1A1CYP1A2CYP2A6MEN1MAPT | |
| SCHEMBL1069262 | 0.73 | MAPT (0.36) | CA1CA2CA7CA9CA12 | |
| SCHEMBL21630298 | 0.73 | MAOA (0.40) | CA2CA9CA14ALDH1A1CYP1A2 | |
| SCHEMBL1079342 | 0.72 | ACHE (0.31) | ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | claimed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | claimed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | claimed |
| CN-116323557-A | Cyclobutylamide monoacylglycerol lipase modulators | 詹森药业有限公司 | 2023-06-23 | — | — | CN | claimed |
| US-10239882-B2 | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2019-03-26 | — | — | US | claimed |
| US-20180282338-A1 | SUBSTITUTED 5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC | 2018-10-04 | — | — | US | claimed |
| EP-3215508-A1 | SUBSTITUTED 5-METHYL-[1, 2, 4]TRIAZOLO [1,5-A) PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | Dart NeuroScience (Cayman) Ltd. (KY) | 2017-09-13 | — | — | EP | claimed |
| WO-2016073424-A1 | SUBSTITUTED 5-METHYL-[1, 2, 4] TRIAZOLO [1,5-A) PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2016-05-12 | — | — | WO | claimed |
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | claimed |
| EP-1618107-B1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2010-06-30 | — | — | EP | claimed |
| EP-2186813-A1 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SmithKline Beecham (Cork) Limited (IE) | 2010-05-19 | — | — | EP | claimed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | claimed |
| EP-1611133-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC. CSC, The United States Corporation Company (PR) | 2006-01-04 | — | — | EP | claimed |
| WO-2004094420-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-11-04 | — | — | WO | claimed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| EP-1611133-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC. CSC, The United States Corporation Company (PR) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004094419-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094420-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | CRH, CRHR1, CRHR2 | CA1 1300/4885CA2 2139/4885CA7 2822/4885 |
| US-10239882-B2 | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors | PDE12, PDE2A, PDE3A | CA1 3167/4885CA2 3359/4885CA7 3316/4885 |
| US-20180282338-A1 | SUBSTITUTED 5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE3A | CA1 3167/4885CA2 3359/4885CA7 3316/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | CA1 2357/4885CA2 2654/4885CA7 3930/4885 |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | CRHR2, NR3C2, CRHR1 | CA1 1429/4885CA2 1116/4885CA7 1811/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CA1 2284/4885CA2 2632/4885CA7 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.